Can the Fed’s rate cut change biotech’s ‘new normal’?

[cafead]

via The cut “will be very positive for the biotech capital markets,” said John Maraganore, the former CEO of Alnylam Pharmaceuticals who is currently an advisor to drug startups. “I expect to see a meaningful strengthening of the biotech tape as interest rates decline.”

article source